The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector ...

Valoctocogene roxaparvovec delivers a B-domain–deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a ...

A form of gene therapy has shown significant benefit in men with a severe form of the bleeding disorder hemophilia A. "If approved, this first-generation gene therapy would offer a new choice for care ...

Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene therapy for severe hemophilia A.

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...

FactorTrack, the first customizable mobile application for people with hemophilia A, has been introduced by Bayer HealthCare Pharmaceuticals. With this free, personal and interactive application, it ...

The Company plans to resubmit the Biologics License Application to the FDA in the second quarter of 2022. Credit: Getty Images. Positive 2-year data were announced from a phase 3 study evaluating ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Over the past ...